Top 9 acinetobacter baumannii treatment in 2022

Below are the best information and knowledge on the subject acinetobacter baumannii treatment compiled and compiled by our own team alltopus:

1. Treatment of Acinetobacter infections – PubMed

Author: www.uptodate.com

Date Submitted: 08/12/2021 08:57 PM

Average star voting: 5 ⭐ ( 14597 reviews)

Summary: Pooled data suggest that infections caused by A. baumannii, especially those with inappropriate treatment, are associated with considerable attributable mortality. The optimal treatment for A. baumannii nosocomial infections has not been established, especially for MDR strains. Therefore, well-desig …

Match with the search results: Minocycline — Many resistant strains of A. baumannii are susceptible in vitro to minocycline, which can be given intravenously, and limited ……. read more

Treatment of Acinetobacter infections - PubMed

2. Treatment of Acinetobacter Infections

Author: pubmed.ncbi.nlm.nih.gov

Date Submitted: 05/16/2021 01:41 PM

Average star voting: 4 ⭐ ( 30521 reviews)

Summary: Abstract. Acinetobacter baumannii remains an important and difficult-to-treat pathogen whose resistance patterns result in significant challenges for the clinic

Match with the search results: What the reader will gain: The antibiotics that are usually effective against A. baumannii infections include carbapenems, polymyxins E and B, sulbactam, ……. read more

Treatment of Acinetobacter Infections

3. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment

Author: academic.oup.com

Date Submitted: 03/05/2021 10:24 PM

Average star voting: 3 ⭐ ( 55821 reviews)

Summary:

Match with the search results: Aminoglycosides. Amikacin and tobramycin are the 2 agents that appear to retain activity against many A. baumannii isolates. As with all antimicrobial agents ……. read more

Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment

4. Acinetobacter Medication: Antibiotics

Author: journals.asm.org

Date Submitted: 09/05/2020 12:10 AM

Average star voting: 5 ⭐ ( 43369 reviews)

Summary: Acinetobacter baumannii is a pleomorphic aerobic gram-negative bacillus (similar in appearance to Haemophilus influenzae on Gram stain) commonly isolated from the hospital environment and hospitalized patients. A baumannii is a water organism and preferentially colonizes aquatic environments.

Match with the search results: baumannii ATCC 17961 were treated with ciprofloxacin, daptomycin, or fimsbactin conjugate. Saline treatment was used as a control. All mice in ……. read more

Acinetobacter Medication: Antibiotics

5. Drug Treatment for Multidrug-resistant Acinetobacter baumannii Infections

Author: www.clinicalmicrobiologyandinfection.com

Date Submitted: 05/16/2019 04:38 PM

Average star voting: 3 ⭐ ( 77279 reviews)

Summary: Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections. Here’s what you need to know to prevent these infections.

Match with the search results: …. read more

Drug Treatment for Multidrug-resistant Acinetobacter baumannii Infections

6. Frontiers | Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options | Cellular and Infection Microbiology

Author: emedicine.medscape.com

Date Submitted: 10/14/2019 03:24 PM

Average star voting: 3 ⭐ ( 14779 reviews)

Summary: Acinetobacter baumannii is undoubtedly one of the most successful pathogens responsible for hospital-acquired nosocomial infections in the modern healthcare system. Due to the prevalence of infections and outbreaks caused by multi-drug resistant A. baumannii, few antibiotics are effective for treating infections caused by this pathogen. To overcome this problem, knowledge of the pathogenesis and antibiotic resistance mechanisms of A. baumannii is important. In this review, we summarize current studies on the virulence factors that contribute to A. baumannii pathogenesis, including porins, capsular polysaccharides, lipopolysaccharides, phospholipases, outer membrane vesicles, metal acquisition systems, and protein secretion systems. Mechanisms of antibiotic resistance of this organism, including acquirement of -lactamases, up-regulation of multidrug efflux pumps, modification of aminoglycosides, permeability defects, and alteration of target sites, are also discussed. Lastly, novel prospective treatment options for infections caused by multi-drug resistant A. baumannii are summarized.

Match with the search results: Based on in vitro susceptibility, the most commonly used agents for the treatment of CRAB infections include polymyxins, tigecycline and ……. read more

Frontiers | Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options | Cellular and Infection Microbiology

7. Acinetobacter in Healthcare Settings | HAI | CDC

Author: www.medscape.com

Date Submitted: 06/10/2019 02:58 PM

Average star voting: 5 ⭐ ( 85084 reviews)

Summary: Acinetobacter is a group of germs that can cause infections in the blood, urinary tract and pneumonia, typically in patients in healthcare settings.

Match with the search results: Owing to the propensity of Acinetobacter to develop resistance to antibiotics, current treatment strategies remain limited….. read more

Acinetobacter in Healthcare Settings | HAI | CDC

8. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis – Critical Care

Author: www.frontiersin.org

Date Submitted: 07/19/2020 10:46 PM

Average star voting: 4 ⭐ ( 57214 reviews)

Summary: An optimal therapy for the treatment of pneumonia caused by drug-resistant Acinetobacter baumannii remains unclear. This study aims to compare various antimicrobial strategies and to determine the most effective therapy for pneumonia using a network meta-analysis. Systematic search and quality assessment were performed to select eligible studies reporting one of the following outcomes: all-cause mortality, clinical cure, and microbiological eradication. The primary outcome was all-cause mortality. A network meta-analysis was conducted with a Bayesian approach. Antimicrobial treatments were ranked based on surface under the cumulative ranking curve (SUCRA) value along with estimated median outcome rate and corresponding 95% credible intervals (CrIs). Two treatments were considered significantly different if a posterior probability of superiority (P) was greater than 97.5%. Twenty-three studies evaluating 15 antimicrobial treatments were included. Intravenous colistin monotherapy (IV COL) was selected as a common comparator, serving as a bridge for developing the network. Five treatments ranked higher than IV COL (SUCRA, 57.1%; median all-cause mortality 0.45, 95% CrI 0.41–0.48) for reducing all-cause mortality: sulbactam monotherapy (SUL, 100.0%; 0.18, 0.04–0.42), high-dose SUL (HD SUL, 85.7%; 0.31, 0.07–0.71), fosfomycin plus IV COL (FOS + IV COL, 78.6%; 0.34, 0.19–0.54), inhaled COL plus IV COL (IH COL + IV COL, 71.4%; 0.39, 0.32–0.46), and high-dose tigecycline (HD TIG, 71.4%; 0.39, 0.16–0.67). Those five treatments also ranked higher than IV COL (SUCRA, 45.5%) for improving clinical cure (72.7%, 72.7%, 63.6%, 81.8%, and 90.9%, respectively). Among the five treatments, SUL (P = 98.1%) and IH COL + IV COL (P = 99.9%) were significantly superior to IV COL for patient survival and clinical cure, respectively. In terms of microbiological eradication, FOS + IV COL (P = 99.8%) and SUL (P = 98.9%) were significantly superior to IV COL. This Bayesian network meta-analysis demonstrated the comparative effectiveness of fifteen antimicrobial treatments for drug-resistant A. baumannii pneumonia in critically ill patients. For survival benefit, SUL appears to be the best treatment followed by HD SUL, FOS + IV COL, IH COL + IV COL, HD TIG, and IV COL therapy, in numerical order.

Match with the search results: Antimicrobial resistance poses great limits for therapeutic options in infected patients, especially if the isolates are resistant to carbapenems. Other ……. read more

Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis - Critical Care

9. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0

Author: www.cdc.gov

Date Submitted: 01/28/2020 09:26 PM

Average star voting: 4 ⭐ ( 64006 reviews)

Summary:

Match with the search results: baumannii, few antibiotics are effective for treating infections caused by this pathogen. To overcome this problem, ……. read more

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0

Related Posts

Leave a Reply

Your email address will not be published.